Targeted Protein Degradation– tag –
-
FDA Approval of First PROTAC Vepdegestrant Raises New Challenges in Targeted Protein Degradation Patent Strategy
Elkington and Fife UK Overview The FDA approval of vepdegestrant, the first PROTAC, marks a significant milestone for targeted protein degradation (TPD), bringing complex intellectual property considerations to the forefront. The unique ... -
First Half 2026 Sees 24 New Small-Molecule Approvals: Pioneering PROTAC Vepdegestrant and Oral GLP-1 Orforglipron Enter Market
Chemexpress China Overview Twenty-four small-molecule drugs received their first global approval in the first half of 2026, with 95.8% being oral dosage forms. Key highlights include the approval of the first commercial PROTAC, vepdegest... -
First PROTAC Approval Validates Targeted Protein Degradation as a Breakthrough Modality for Cancer Treatment
Converge Bio Unknown Overview The FDA approval of vepdegestrant, developed by Arvinas and Pfizer, signifies a major milestone for targeted protein degradation (TPD). This first-in-class PROTAC, approved for ER+/HER2-, ESR1-mutated advanc... -
FDA Approves First PROTAC Vepdegestrant (ARV-471) for ER+/HER2- Breast Cancer, Ushering in a New Era of Targeted Protein Degradation
Journal of Medicinal Chemistry - ACS Publications USA Overview On May 1, 2026, the FDA approved vepdegestrant (ARV-471; Veppanu), making it the first heterobifunctional PROTAC protein degrader approved for clinical practice. Indicated fo... -
FDA Approval a TPD Turning Point? Maria Soloveychik Cautions Single Molecule Success Doesn’t Guarantee All Targets
Drug Discovery Online USA Overview Maria Soloveychik acknowledges the FDA approval of a bivalent degrader as a crucial 'proof point' for the Targeted Protein Degradation (TPD) field but warns that this single molecular success does not n... -
bioRxiv Reports Novel AR Molecular Glue Degrader GZL626 Inhibits Prostate Cancer Cell Proliferation, Effective Against AR-V7
bioRxiv USA Overview A preprint published on bioRxiv reports a novel androgen receptor (AR) molecular glue degrader, GZL626. GZL626 was shown to induce proteasome-dependent degradation of both full-length AR and the AR splicing variant A... -
FDA Approves First-in-Class PROTAC Degrader Vepdegestrant for ESR1-Mutated Breast Cancer, Improving Progression-Free Survival by 43%
Dana-Farber Cancer Institute USA Overview The U.S. FDA has approved vepdegestrant (Veppanu), a first-in-class PROTAC (Proteolysis-Targeting Chimera) degrader, for patients with ER-positive, HER2-negative metastatic breast cancer harborin... -
Nurix Therapeutics and Roche Secure HSR Clearance for Global Co-Development and Co-Commercialization Agreement of BTK Degrader Bexobrutideg
Nurix Therapeutics USA Overview Nurix Therapeutics announced HSR clearance for its global co-development and co-commercialization agreement with Roche for the BTK degrader bexobrutideg. Bexobrutideg is advancing in malignant hematology, ... -
Tango Therapeutics Unveils TNG961, First Selective Oral HBS1L Molecular Glue Degrader for FOCAD-Deleted Cancers, a New Precision Oncology Strategy
AACR Journals (Cancer Discovery) USA Overview Tango Therapeutics announced the development of TNG961, the first selective oral HBS1L molecular glue degrader targeting FOCAD-deleted cancers. TNG961 induces translational arrest by disrupti... -
First Oral ER PROTAC Vepdegestrant Gains FDA Approval, Ushering New Era in Targeted Protein Degradation
MDPI Switzerland Overview The field of Targeted Protein Degradation (TPD) marks a significant milestone with the FDA approval of vepdegestrant (VEPPANU, ARV-471), the first oral estrogen receptor (ER) targeted PROTAC, co-developed by Arv...
